Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Pulmonology, Respiratory
aTyr Pharma, Inc. (NASDAQ: LIFE)

Organization & Developments: Atyr

Parents

*Ashlock, formerly a researcher at the NIH, was one of the people at the nonprofit Cystic Fibrosis Foundation who helped craft a partnership that poured more than $75 million into developing a cystic fibrosis drug with Cambridge, MA-based Vertex Pharmaceuti
*Preclinical-stage biopharmaceutical company focused on inflammation, autoimmune, hematopoietic and metabolic disorders
*The company (pronounced A-tire) is working on a new class of natural proteins called “physiocrines” that send signals between cells.
*The company dropped a hint of the kind of partnerships it has in mind when it hired Melissa Ashlock as its new vice president of external scientific alliances and human genetics.
2011: aTyr Pharma Crafts Plan to Strike Balance Between Nonprofits, and Really Big For-Profits (2011)
2018: Troubled aTyr axes 30% of its staff as it wipes a preclinical slate clean – Endpoints News
2021: LIFE +67% Phase 1b/2a; LPTX +21% Mixed ESMO… • BioPharmCatalyst
2025: aTyr flunks phase 3 lung disease trial, deflating stock, but still plans talks with FDA
2025: aTyr Pharma: Estimating Their Phase 3 Lung Disease Trial Outcome
2025: aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating
2025: aTyr Pharma: Interesting Drug, Difficult Target Market_seekingalpha.com
2025: aTyr: Promising Data, But Cash May Be An Issue